Research Study


A middle-aged black woman is sitting on the couch holding a tablete and a bottole of prescription pills.

UPDATE: The STOP COVID 2 trial, which is testing fluvoxamine for treatment of early COVID-19, has stopped enrolling new participants.  The trial will continue to follow all current participants to completion.  We thank all participants and partners for this study and look forward to reporting the results as soon as possible.  Patients currently enrolled in the trial should finish their assigned doses of therapy and are asked to complete longer term follow up for the additional outcomes including post-COVID recovery.

We are continually learning more about COVID-19 and as a result, we have been able to adapt our public health guidance, improve care for patients with the virus and develop vaccines. However, more research is required to better understand COVID-19 and how to best treat it.

Scientists at Women’s College Hospital are collaborating with McGill University on a new study testing the impact of a common antidepressant medication, fluvoxamine, on COVID-19 symptoms. The goal is to see if fluvoxamine can help reduce the severity of COVID symptoms. Our study is a partner study to a U.S based trial lead by Washington University in St. Louis.

WCH is looking for symptomatic patients with COVID-19 to take part in this clinical trial. Participants will be randomly assigned to either take fluvoxamine or a placebo (e.g. vitamin pill) for 15 days. Fluvoxamine belongs to a class of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs). It is approved in Canada and has decades of safety data.

You may be eligible to participate in this study if you:  

  1. Are COVID positive (per lab, physician report, or self-report)
  2. Currently self-isolating at home
  3. Are symptomatic with any of the following: fever, cough, muscle pain or ache, shortness of breath, chest pain, diarrhea, nausea, vomiting, inability to smell or taste, sore throat, nasal congestion.
  4. Are experiencing six of fewer total days of symptoms
  5. And have one of the following risk factors:
    •    Are 40 years of age or older
    •    Self-identify as Black, Hispanic, Indigenous or South Asian
    •    Experience one or more chronic medical conditions (e.g. obesity, hypertension, diabetes, cardiac, respiratory disease or an immune disorder like rheumatoid arthritis or lupus)
    •    COVID-19 varients of concern (namely the UK, South African and Brazilian variants).

This study is funded by the Research Institute of McGill University Health Centre. Patients participating in the trial may also be enrolled in our COVIDCare@Home program.
If you are interested in participating in the study or would like to learn more about STOP COVID 2, please visit: or email

For more information, please contact the study coordinator:
Maria Michalowska | (416) 351-3732 ext. 2302

Fully affiliated with

A member of

Council of Academic Hospitals of Ontario (CAHO)